中国全科医学2012,Vol.15Issue(24):2749-2754,6.DOI:10.3969/j.issn.1007-9572.2012.08.087
磷脂酰肌醇3-激酶/哺乳动物雷帕霉素靶蛋白抑制剂在乳腺癌治疗中的研究进展
Inhibitor in Breast CancerLatest Research Progress of PI3K/mTOR
摘要
Abstract
The PI3K/AKT/mTOR signaling pathway is involved in the inhibition of tumor cell apoptosis, the promo-tion of cell survival, cell cycle regulation, tumor angiogenesis, invasion and metastasis and therefore plays an important role in tumorigenesis, tumor growth, tumor treatment and patients' prognosis. Recent studies showed this signaling pathway is closely related to breast cancer, making it a new therapeutic target and a hotspot in breast cancer research. Pre - clinical studies have confirmed that PI3K inhibitors and mTOR inhibitors achieve anticancer effects by targeting different targets of the PI3K/AKT/mT0R signaling pathway. Among the PI3K inhibitors, some medicines only target PI3K, whereas others target both PI3K and mTOR. Currently, researchers tend to focus on molecular targets based on different PI3K subtypes to achieve more targeted and specific inhibition of the PI3K pathway. However, the clinical efficacy and efficiency of these inhibitors need to be further studied. The mTOR inhibitors target mTORCl and have been become relatively well - developed targeted therapies for the PI3K/AKT/ mTOR pathway. Rapamycin derivatives have been studied in phase Ⅱ/Ⅲ clinical trials in breast cancer, and these derivatives a-chieved positive results in the treatment of metastatic breast cancer when combined with endocrine therapy or Her - 2 - targeted therapies.关键词
乳腺肿瘤/1-磷脂酰肌醇3-激酶/哺乳动物雷帕霉素靶蛋白Key words
Breast neoplasms/ 1 - phosphatidylinositol 3 - kinase/ Mammalian target of rapamycin分类
医药卫生引用本文复制引用
张晟,张霄蓓,张瑾..磷脂酰肌醇3-激酶/哺乳动物雷帕霉素靶蛋白抑制剂在乳腺癌治疗中的研究进展[J].中国全科医学,2012,15(24):2749-2754,6.基金项目
科技部国际合作重大项目(2010DFB30270) (2010DFB30270)